Biotechnologia Acta


  • Increase font size
  • Default font size
  • Decrease font size
Print PDF

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

"Biotechnologia Acta" V. 11, No 3, 2018
Р. 27-46, Bibliography 198, English
Universal Decimal Classification: [577.112.083/616.931]:[615(331+371+375)+616-006.04]


Manoilov K.Y.

Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Kyiv

The aim of the review was to analyze the literature data related to the application of a variety of diphtheria toxin derivatives. Although studies of the diphtheria toxin interaction with sensitive and resistant mammalian cells have been held for a relatively long time, there are still some unresolved issues concerning the molecular mechanisms of diphtheria toxin functioning. Native diphtheria toxin  and parts of its molecule which preserves toxicity are used as instruments in the newest biotechnological methods of specific cell subtype ablation in multicellular organisms. New recombinant derivatives of diphtheria toxin are periodically obtained in the laboratories throughout the world. Most of these analogs of diphtheria toxin  are used in biological studies as convenient tools for analysis of the functions of the natural toxin. A non-toxic analog of diphtheria toxin, protein CRM197, is used in clinical practice as a component of vaccines and as an anticancer agent. Diphtheria toxin  -based targeted toxin therapy is another perspective trend for cancer therapy. Therefore, studying of diphtheria toxin derivatives is of a great relevance for biotechnology and medicine.

Key words: cell ablation, CRM197, diphtheria toxin, immunogenicity, targeted toxin therapy, toxoid.

Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2018

  • References

    • 1. Alouf J. E., Freer J. H. The Comprehensive Sourcebook of Bacterial Protein Toxins, Second Edition. 2nd ed. Academic Press, 1999.
      2. Fukagawa S., Yotsumoto F., Odawara T., Manabe S., Ishikawa T., Yasunaga S., Miyamoto S. Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy. Anticancer Res. 2017, 37 (7), 3891–3896.
      3. Miyamoto S., Yotsumoto F., Ueda T., Fukami T., Sanui A., Miyata K., Nam S. O., Fukagawa S., Katsuta T., Maehara M., Kondo H., Miyahara D., Shirota K., Yoshizato T., Kuroki M., Nishikawa H., Saku K., Tsuboi Y., Ishitsu ka K. BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. BMC Cancer. 2017, 17 (1), 89.
      4. Nam S.O., Yotsumoto F., Miyata K., Suzaki Y., Yagi H., Odawara T., Manabe S., Ishikawa T., Kuroki M., Mekada E., Miyamoto S. Preclinical Study of BK-UM, a Novel Inhibitor of HB-EGF, for Ovarian Cancer Therapy. Anticancer Res. 2014, 34 (8), 4615–4620.
      5. Selim S. A., Mohamed F. H., Hessain A. M., Moussa I. M. Immunological characterization of diphtheria toxin recovered from Corynebacterium pseudotuberculosis. Saud. J. Biol. Sci. 2016, 23 (2), 282–287.
      6. Greenfield L., Bjorn M. J., Horn G., Fong D., Buck G. A., Collier R. J., Kaplan D. A. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc. Natl. Acad. Sci. U.S.A. 1983, 80 (22), 6853–6857.
      7. Freeman V.J. Studies on the virulence of bacteriophage infected strains of Corynebacterium diphtheriae. J. Bacteriol. 1951, 61 (6), 675–688.
      8. Freeman V. J., Morse I. U. Further observations on the change to virulence of bacteriophageinfected avirulent strains of Corynebacterium diphtheriae. J. Bacteriol. 1952, 63 (3), 407–414.
      9. Guedon E., Helmann J. D. Origins of metal ion selectivity in the DtxR/MntR family of metalloregulators. Mol. Microbiol. 2003, 48 (2), 495–506.
      10. Spiering M. M., Ringe D., Murphy J. R., Marletta M. A. Metal stoichiometry and functional studies of the diphtheria toxin repressor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (7), 3808–3813.
      11. Smith W. P., Tai P. C., Murphy J. R., Davis B. D. Precursor in cotranslational secretion of diphtheria toxin. J. Bacteriol. 1980, 141 (1), 184–189.
      12. Schneewind O., Missiakas D. M. Protein secretion and surface display in Grampositive bacteria. Philos. Trans. R. Soc. Lond., B., Biol. Sci. 2012, 367 (1592), 1123–1139.
      13. Collier R. J. Diphtheria toxin: mode of action and structure. Bacteriol. Rev. 1975, 39 (1), 54–85.
      14. Uchida T., Pappenheimer A. M., Greany R. Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. J. Biol. Chem. 1973, 248 (11), 3838–3844.
      15. Bell C.E., Eisenberg D. Crystal structure of nucleotide-free diphtheria toxin. Biochemistry. 1997, 36 (3), 481–488.
      16. Eisenberg D., Bell C. E., Bennett M. J., Collier R. J., Schlunegger M. P., Steere B. A., Weiss M. S. A Structure-Based Model of Diphtheria Toxin Action. In: Protein Toxin Structure. Springer, Berlin, Heidelberg. 1996, 25–47.
      17. Choe S., Bennett M. J., Fujii G., Curmi P. M., Kantardjieff K. A., Collier R. J., Eisenberg D. The crystal structure of diphtheria toxin. Nature. 1992, 357 (6375), 216–222.
      18. Simpson J. C., Smith D. C., Roberts L. M., Lord J. M. Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin. Exp. Cell Res. 1998, 239 (2), 293–300.
      19. Olsnes S., Sandvig K. How protein toxins enter and kill cells. In: Immunotoxins
      (Frankel A.E. ed.). Martinus Nijhoff Publishing, Boston. 1987, 39–74.
      20. Kagan B. L., Finkelstein A., Colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc. Natl. Acad. Sci. U.S.A. 1981, 78 (8), 4950–4954.
      21. Donovan J. J., Simon M. I., Draper R. K., Montal M. Diphtheria toxin forms transmembrane channels in planar lipid bilayers. Proc. Natl. Acad. Sci. U.S.A. 1981, 78 (1), 172–176.
      22. Naglich J. G., Metherall J. E., Russell D. W., Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparinbinding EGF-like growth factor precursor. Cell. 1992, 69 (6), 1051–1061.
      23. Abraham J. A., Damm D., Bajardi A., Miller J., Klagsbrun M., Ezekowitz R. A. Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. Biochem. Biophys. Res. Commun. 1993, 190 (1), 125–133.
      24. Louie G. V., Yang W., Bowman M. E., Choe S. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol. Cell. 1997, 1 (1), 67–78.
      25. Higashiyama S., Lau K., Besner G. E., Abraham J. A., Klagsbrun M. Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J. Biol. Chem. 1992, 267 (9), 6205–6212.
      26. Mitamura T., Higashiyama S., Taniguchi N., Klagsbrun M., Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGFlike growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J. Biol. Chem. 1995, 270 (3), 1015–1019.
      27. Shen W. H., Choe S., Eisenberg D., Collier R. J. Participation of lysine 516 and phenylalanine 530 of diphtheria toxin in receptor recognition. J. Biol. Chem. 1994, 269 (46), 29077–29084.
      28. Nakamura K., Iwamoto R., Mekada E. Membrane-anchored heparin-binding EGFlike growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites. J. Cell Biol. 1995, 129 (6), 1691–1705.
      29. Iwamoto R., Mekada E. Heparin-binding EGF-like growth factor: a juxtacrine growth factor. Cytokine Growth Factor Rev. 2000, 11 (4), 335–344.
      30. Hasuwa H., Shishido Y., Yamazaki A., Kobayashi T., Yu X., Mekada E. CD9 amino acids critical for upregulation of diphtheria toxin binding. Biochem. Biophys. Res. Commun. 2001, 289 (4), 782–790.
      31. Iwamoto R., Higashiyama S., Mitamura T., Taniguchi N., Klagsbrun M., Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J. 1994, 13 (10), 2322–2330.
      32. Cha J. H., Brooke J. S., Ivey K. N., Eidels L. Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity. J. Biol. Chem. 2000, 275 (10), 6901–6907.
      33. Cobbett L. The Resistance of Rats to Diphtheria Toxin. Br. Med. J. 1899, 1 (1998), 902–903.
      34. Pappenheimer A. M. Diphtheria Toxin. Ann. Rev. Biochem. 1977, 46 (1), 69–94.
      35. Moehring T. J., Moehring J. M. Interaction of diphtheria toxin and its active subunit, fragment A, with toxin-sensitive and toxinresistant cells. Infect. Immun. 1976, 13 (5), 1426–1432.
      36. Cha J. H., Brooke J. S., Eidels L. Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis. Mol. Microbiol. 1998, 29 (5), 1275–1284. B. Diphtheria toxin does not enter resistant cells by receptormediated endocytosis. Infect. Immun. 1983, 42 (2), 812–817.
      38. Mitamura T., Umata T., Nakano F., Shishido Y., Toyoda T., Itai A., Kimura H., Mekada E. Structure-function analysis of the diphtheria toxin receptor toxin binding site by sitedirected mutagenesis. J. Biol. Chem. 1997, 272 (43), 27084–27090.
      39. Naglich J. G., Metherall J. E., Russell D. W., Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparinbinding EGF-like growth factor precursor. Cell. 1992, 69 (6), 1051–1061.
      40. El Hage T., Decottignies P., Authier F. Endosomal proteolysis of diphtheria toxin without toxin translocation into the cytosol of rat liver in vivo. FEBS J. 2008, 275 (8), 1708–1722.
      41. Heagy W. E., Neville D. M. J. Kinetics of protein synthesis inactivation by diphtheria toxin in toxin-resistant L cells. Evidence for a low efficiency receptor-mediated transport system. J. Biol. Chem. 1981, 256 (24), 12788–12792.
      42. Didsbury J. R., Moehring J. M., Moehring T. J. Binding and uptake of diphtheria toxin by toxin-resistant Chinese hamster ovary and mouse cells. Mol. Cell. Biol. 1983, 3 (7), 1283–1294.
      43. Labyntsev A. J., Kolybo D. V., Yurchenko E. S., Kaberniuk A. A., Korotkevych N. V., Komisarenko S. V. Effect of the T-domain on intracellular transport of diphtheria toxin. Ukr. Biochem. J. 2014, 86 (3), 77–87.
      44. Labyntsev A. J., Korotkevych N. V., Kolybo D. V., Komisarenko S. V. Effect of diphtheria toxin T-domain on endosomal pH. Ukr. Biochem. J. 2015, 87 (4), 13–23.
      45. Higashiyama S., Abraham J. A., Miller J., Fiddes J. C., Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991, 251 (4996), 936–939.
      46. Iwamoto R., Mekada E. ErbB and HB-EGF signaling in heart development and function. Cell Struct. Funct. 2006, 31 (1), 1–14.
      47. Raab G., Klagsbrun M. Heparin-binding EGFlike growth factor. Biochim. Biophys. Acta. 1997, 1333 (3), F179–199.
      48. Higashiyama S., Abraham J. A., Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J. Cell Biol. 1993, 122 (4), 933–940.
      49. Mine N., Iwamoto R., Mekada E. HB-EGF promotes epithelial cell migration in eyelid development. Development. 2005, 132 (19), 4317–4326.
      50. Marikovsky M., Vogt P., Eriksson E., Rubin J. S., Taylor W. G., Joachim S., Klagsbrun M. Wound fluid-derived heparinbinding EGF-like growth factor (HB-EGF) is synergistic with insulin-like growth factor-I for Balb/MK keratinocyte proliferation. J. Invest. Dermatol. 1996, 106 (4), 616–621.
      51. Shirakata Y., Kimura R., Nanba D., Iwamoto R., Tokumaru S., Morimoto C., Yokota K., Nakamura M., Sayama K., Mekada E., Higashiyama S., Hashimoto K. Heparinbinding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J. Cell. Sci. 2005, 118 (Pt 11), 2363–2370.
      52. Tokumaru S., Higashiyama S., Endo T., Nakagawa T., Miyagawa J. I., Yamamori K., Hanakawa Y., Ohmoto H., Yoshino K., Shirakata Y., Matsuzawa Y., Hashimoto K., Taniguchi N. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J. Cell Biol. 2000, 151 (2), 209–220.
      53. Kimura R., Iwamoto R., Mekada E. Soluble form of heparin-binding EGF-like growth factor contributes to retinoic acid-induced epidermal hyperplasia. Cell Struct. Funct. 2005, 30 (2), 35–42.
      54. Asakura M., Kitakaze M., Takashima S., Liao Y., Ishikura F., Yoshinaka T., Ohmoto H., Node K., Yoshino K., Ishiguro H., Asanuma H., Sanada S., Matsumura Y., Takeda H., Beppu S., Tada M., Hori M., Higashiyama S. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HBEGF: metalloproteinase inhibitors as a new therapy. Nat. Med. 2002, 8 (1), 35–40.
      55. Miyagawa J., Higashiyama S., Kawata S., Inui Y., Tamura S., Yamamoto K., Nishida M., Nakamura T., Yamashita S., Matsuzawa Y. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J. Clin. Invest. 1995, 95 (1), 404–411.
      56. Takemura T., Hino S., Kuwajima H., Yanagida H., Okada M., Nagata M., Sasaki S., Barasch J., Harris R.C., Yoshioka K. Induction of collecting duct morphogenesis in vitro by heparin-binding epidermal growth factor-like growth factor. J. Am. Soc. Nephrol. 2001, 12 (5), 964–972.
      57. Das S. K., Wang X. N., Paria B. C., Damm D., Abraham J. A., Klagsbrun M., Andrews G. K., Dey S. K. Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation. Development. 1994, 120 (5), 1071–1083.
      58. Powell P. P., Klagsbrun M., Abraham J. A., Jones R. C. Eosinophils expressing heparinbinding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension. Am. J. Pathol. 1993, 143 (3), 784–793.
      59. Fu S. l., Bottoli I., Goller M., Vogt P. K. Heparin-binding epidermal growth factorlike growth factor, a v-Jun target gene, induces oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96 (10), 5716–5721.
      60. Kaberniuk A. A., Labyntsev A. I., Kolybo D. V., Oliĭnyk O. S., Redchuk T. A., Korotkevych N. V., Horchev V. F., Karakhim S. O., Komisarenko S. V. Fluorescent derivatives of diphtheria toxin subunit B and their interaction with Vero cells. Ukr. Biokhim. Zh. (1999). 2009, 81 (1), 67–77. (In Ukrainian).
      61. Uchida T., Pappenheimer A. M., Harper A. A. Diphtheria toxin and related proteins. 3. Reconstitution of hybrid “diphtheria toxin” from nontoxic mutant proteins. J. Biol. Chem. 1973, 248 (11), 3851–3854.
      62. Kageyama T., Ohishi M., Miyamoto S., Mizushima H., Iwamoto R., Mekada E. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J. Biochem. 2007, 142 (1), 95–104.
      63. Qiao J., Ghani K., Caruso M. Diphtheria toxin mutant CRM197 is an inhibitor of protein synthesis that induces cellular toxicity. Toxicon. 2008, 51 (3), 473–477.
      64. Kimura Y., Saito M., Kimata Y., Kohno K. Transgenic mice expressing a fully nontoxic diphtheria toxin mutant, not CRM197 mutant, acquire immune tolerance against diphtheria toxin. J. Biochem. 2007, 142 (1), 105–112.
      65. Mekada E., Uchida T. Binding properties of diphtheria toxin to cells are altered by mutation in the fragment A domain. J. Biol. Chem. 1985, 260 (22), 12148–12153.
      66. Hu V. W., Holmes R. K. Single mutation in the A domain of diphtheria toxin results in a protein with altered membrane insertion behavior. Biochim. Biophys. Acta. 1987, 902 (1), 24–30.
      67. Malito E., Bursulaya B., Chen C., Surdo P. L., Picchianti M., Balducci E., Biancucci M., Brock A., Berti F., Bottomley M. J., Nissum M., Costantino P., Rappuoli R., Spraggon G. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc. Natl. Acad. Sci. USA. 2012.
      68. Salmas R. E., Mestanoglu M., Unlu A., Yurtsever M., Durdagi S. Mutated form (G52E) of inactive diphtheria toxin CRM197: molecular simulations clearly display effect of the mutation to NAD binding. J. Biomol. Struct. Dyn. 2016, 34 (11), 2462–2468.
      69. Papini E., Colonna R., Schiavo G., Cusinato F., Tomasi M., Rappuoli R., Montecucco C. Diphtheria toxin and its mutant crm 197 differ in their interaction with lipids. FEBS Lett. 1987, 215 (1), 73–78.
      70. Giannini G., Rappuoli R., Ratti G. The aminoacid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucl. Acids Res. 1984, 12 (10), 4063–4069.
      71. Bigio M., Rossi R., Nucci D., Antoni G., Rappuoli R., Ratti G. Conformational changes in diphtheria toxoids. Analysis with monoclonal antibodies. FEBS Lett. 1987, 218 (2), 271–276.
      72. Kaczorek M., Delpeyroux F., Chenciner N., Streeck R. E., Murphy J. R., Boquet P., Tiollais P. Nucleotide sequence and expression of the diphtheria tox228 gene in Escherichia coli. Science. 1983, 221 (4613), 855–858.
      73. Laird W., Groman N. Isolation and characterization of tox mutants of corynebacteriophage beta. J. Virol. 1976, 19 (1), 220–227.
      74. Riedel C. J., Muraszko K. M., Youle R. J. Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons. Proc. Natl. Acad. Sci. U.S.A. 1990, 87 (13), 5051–5055.
      75. Greenfield L., Johnson V. G., Youle R. J. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science. 1987, 238 (4826), 536–539.
      76. Bacha P., Murphy J. R. Isolation and characterization of extragenic suppressor strains of Corynebacterium diphtheriae. J. Bacteriol. 1978, 136 (3), 1135–1142.
      77. Bacha P., Reichlin S. Systemic toxicity of diphtheria toxin-related fragments (CRM26, CRM45), a hormone-toxin hybrid protein (TRH-CRM45), and ricin A. Proc. Soc. Exp. Biol. Med. 1986, 181 (1), 131–138.
      78. Dell’Arciprete L., Colombatti M., Rappuoli R.,Tridente G. A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity. J. Immunol. 1988, 140 (7), 2466–2471.
      79. Papini E., Schiavo G., Tomasi M., Colombatti M., Rappuoli R., Montecucco C. Lipid interaction of diphtheria toxin and mutants with altered fragment B. 2. Hydrophobic photolabelling and cell intoxication. Eur. J. Biochem. 1987, 169 (3), 637–644.
      80. Shafiee F., Rabbani M., Behdani M., Jahanian-Najafabadi A. Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: An attempt for production of a new vaccine against diphtheria. Res. Pharm. Sci. 2016, 11 (5), 428–434.
      81. Barbieri J. T., Collier R. J. Expression of a mutant, full-length form of diphtheria toxin in Escherichia coli. Infect. Immun. 1987, 55 (7), 1647–1651.
      82. Shmelev V. A., Perovskaia O. N., Kopylov P. K., Nosova L. I., Popov S. G. Synthesis, secretion, and proteolytic degradation of diphtheria toxin in Escherichia coli. Mol. Gen. Mikrobiol. Virusol. 1991, (10), 3–8.
      83. Hemilä H., Glode L. M., Palva I. Production of diphtheria toxin CRM228 in B. subtilis. FEMS Microbiol. Lett. 1989, 53 (1–2), 193–198.
      84. Zhou J., Petracca R. Secretory expression of recombinant diphtheria toxin mutants in B. subtilis. J. Tongji Med. Univ. 1999, 19 (4), 253–256.
      85. Studier F. W. Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system. J. Mol. Biol. 1991, 219 (1), 37–44.
      86. Stefan A., Conti M., Rubboli D., Ravagli L., Presta E., Hochkoeppler A. Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli. J. Biotechnol. 2011, 156 (4), 245–252. doi: 10.1016/j.jbiotec. 2011.08.024.
      87. Manoilov K. Y., Gorbatiuk O. B., Usenko M. O., Shatursky O. Y., Borisova T. O., Kolybo D. V. The characterization of purifed recombinant protein CRM197 as a tool to study diphtheria toxin. Dopov. Nats. akad. nauk Ukr. 2016, 9, 124–133. (In Ukranian).
      88. Mahamad P., Boonchird C., Panbangred W. High level accumulation of soluble diphtheria toxin mutant (CRM197) with co-expression of chaperones in recombinant Escherichia coli. Appl. Microbiol. Biotechnol. 2016, 100 (14), 6319–6330.
      89. Dukhovlinov I. V., Fedorova E. A., Bogomolova E. G., Dobrovolskaya O. A., Chernyaeva E. N., Al-Shekhadat R. I., Simbirtsev A. S. Production of recombinant protein CRM197 in Escherichia coli. Russian Journal of Infection and Immunity. 2015, 5 (1), 37. (In Russian).
      90. Kaberniuk A. A., Oliinyk O. S., Redchuk T. A., Romaniuk S. I., Kolybo D. V., Komisarenko S. V. Cloning of recombinant subunits of Corynebacterium diphtheriae diphtheria toxin and their expression in Escherichia coli. Dopov. Nats. akad. nauk Ukr. 2008, 3, 160–166. (In Ukrainian).
      91. Lee C. W., Lee S. F., Halperin S. A. Expression and Immunogenicity of a Recombinant Diphtheria Toxin Fragment A in Streptococcus gordonii. Appl. Environ. Microbiol. 2004, 70 (8), 4569–4574.
      92. Nascimento D. V., Lemes E. M. B., Queiroz J. L. S., Silva Jr. J. G., Nascimento H. J., Silva E. D., Hirata Jr. R., Dias A. A. S. O., Santos C. S., Pereira G. M. B., Mattos-Guaraldi A. L., Armoa G. R. G. Expression and purification of the immunogenically active fragment B of the Park Williams 8 Corynebacterium diphtheriae strain toxin. Braz. J. Med. Biol. Res. 2010, 43 (5), 460–466.
      93. Johnson N., Pickett M. A., Watt P. J., Clarke I. N., Heckels J. E. Construction of an epitope vector utilising the diphtheria toxin B-subunit. FEMS Microbiol. Lett. 1997, 146 (1), 91–96.
      94. Suzuki K., Mizushima H., Abe H., Iwamoto R., Nakamura H., Mekada E. Identification of diphtheria toxin R domain mutants with enhanced inhibitory activity against HBEGF. J. Biochem. 2015, 157 (5), 331–343.
      95. Kumar A., Das G., Bose B. Recombinant receptor-binding domain of diphtheria toxin increases the potency of curcumin by enhancing cellular uptake. Mol. Pharm. 2014, 11 (1), 208–217.
      96. Esbensen Q. Y., Falnes P. O., Olsnes S., Madshus I. H. Subcloning and characterization of the binding domain of fragment B of diphtheria toxin. Biochem. J. 1993, 294 (Pt 3), 663–666.
      97. Labyntsev A. J., Korotkevych N. V., Manoilov K. J., Kaberniuk A. A., Kolybo D. V., Komisarenko S. V. Recombinant fluorescent models for studying the diphtheria toxin. Russ. J. Bioorg. Chem. 2014, 40 (4), 401–409.
      98. Labyntsev A. I., Korotkevich N. V., Kaberniuk A. A., Romaniuk S. I., Kolybo D. V., Komisarenko S. V. Interaction of diphtheria toxin B subunit with sensitive and insensitive mammalian cells. Ukr. Biokhim. Zh. (1999). 2010, 82 (6), 65–75. (In Ukranian).
      99. Blanke S. R., Huang K., Collier R. J. Activesite mutations of diphtheria toxin: role of tyrosine-65 in NAD binding and ADPribosylation. Biochemistry. 1994, 33 (51), 15494–15500.
      100. Wilson B. A., Blanke S. R., Reich K. A., Collier R. J. Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity. J. Biol. Chem. 1994, 269 (37), 23296–23301.
      101. Blanke S. R., Huang K., Wilson B. A., Papini E., Covacci A., Collier R. J. Active-site mutations of the diphtheria toxin catalytic domain: role of histidine-21 in nicotinamide adenine dinucleotide binding and ADPribosylation of elongation factor 2. Biochemistry. 1994, 33 (17), 5155–5161.
      102. Tweten R. K., Barbieri J. T., Collier R. J. Diphtheria toxin. Effect of substituting aspartic acid for glutamic acid 148 on ADPribosyltransferase activity. J. Biol. Chem. 1985, 260 (19), 10392–10394.
      103. Johnson V. G., Nicholls P. J. Histidine 21 does not play a major role in diphtheria toxin catalysis. J. Biol. Chem. 1994, 269 (6), 4349–4354.
      104. Papini E., Schiavo G., Rappuoli R., Montecucco C. Histidine-21 is involved in diphtheria toxin NAD+ binding. Toxicon. 1990, 28 (6), 631–635.
      105. Fu H., Blanke S. R., Mattheakis L. C., Collier R. J. Selection of diphtheria toxin active-site mutants in yeast. Rediscovery of glutamic acid-148 as a key residue. Adv. Exp. Med. Biol. 1997, 41945–41952.
      106. Zhao G., London E. Behavior of diphtheria toxin T domain containing substitutions that block normal membrane insertion at Pro345 and Leu307: control of deep membrane insertion and coupling between deep insertion of hydrophobic subdomains. Biochemistry. 2005, 44 (11), 4488–4498.
      107. Kaul P., Silverman J., Shen W. H., Blanke S. R., Huynh P. D., Finkelstein A., Collier R. J. Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci. 1996, 5 (4), 687–692.
      108. Johnson V. G., Youle R. J. A point mutation of proline 308 in diphtheria toxin B chain inhibits membrane translocation of toxin conjugates. J. Biol. Chem. 1989, 264 (30), 17739–17744.
      109. O’Keefe D., Collier R. J. Cloned diphtheria toxin within the periplasm of Escherichia coli causes lethal membrane damage at low pH. Proc. Natl. Acad. Sci. U.S.A. 1989, 86 (1), 343–346.
      110. O’Keefe D. O., Cabiaux V., Choe S., Eisenberg D., Collier R. J. pH-dependent insertion of proteins into membranes: B-chain mutation of diphtheria toxin that inhibits membrane translocation, Glu-349----Lys. Proc. Natl. Acad. Sci. U.S.A. 1992, 89 (13), 6202–6206.
      111. Rodnin M. V., Kyrychenko A., Kienker P., Sharma O., Posokhov Y. O., Collier R. J., Finkelstein A., Ladokhin A. S. Conformational Switching of the Diphtheria Toxin T Domain. J. Mol. Biol. 2010.
      112. Antignani A., Youle R. J. Endosome fusion induced by diphtheria toxin translocation domain. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (23), 8020–8025.
      113. Cabiaux V., Mindell J., Collier R. J. Membrane translocation and channelforming activities of diphtheria toxin are blocked by replacing isoleucine 364 with lysine. Infect. Immun. 1993, 61 (5), 2200–2202.
      114. Ren J., Sharpe J. C., Collier R. J., London E. Membrane Translocation of Charged Residues at the Tips of Hydrophobic Helices in the T Domain of Diphtheria Toxin†. Biochemistry. 1999, 38 (3), 976–984.
      115. Senzel L., Gordon M., Blaustein R. O., Oh K. J., Collier R. J., Finkelstein A. Topography of Diphtheria Toxin’s T Domain in the Open Channel State. J. Gen. Physiol. 2000, 115 (4), 421–434.
      116. Kienker P. K., Wu Z., Finkelstein A. Topography of the TH5 Segment in the Diphtheria Toxin T-Domain Channel. J. Membr. Biol. 2016, 249 (1–2), 181–196.
      117. Kienker P. K., Wu Z., Finkelstein A. Mapping the membrane topography of the TH6-TH7 segment of the diphtheria toxin T-domain channel. J. Gen. Physiol. 2015, 145 (2), 107–125.
      118. Vargas-Uribe M., Rodnin M. V., Kienker P., Finkelstein A., Ladokhin A. S. Crucial Role of H322 in Folding of the Diphtheria Toxin T-Domain into the Open-Channel State. Biochemistry. 2013, 52 (20), 3457–3463.
      119. Rodnin M. V., Kyrychenko A., Kienker P., Sharma O., Vargas-Uribe M., Collier R. J., Finkelstein A., Ladokhin A. S. Replacement of C-terminal histidines uncouples membrane insertion and translocation in diphtheria toxin T-domain. Biophys. J. 2011, 101 (10), L41–43.
      120. Wu Z., Jakes K. S., Samelson-Jones B. S., Lai B., Zhao G., London E., Finkelstein A. Protein translocation by bacterial toxin channels: a comparison of diphtheria toxin and colicin Ia. Biophys. J. 2006, 91 (9), 3249–3256.
      121. Finkelstein A., Oh K. J., Senzel L., Gordon M., Blaustein R. O., Collier R. J. The diphtheria toxin channel-forming T-domain translocates its own NH2-terminal region and the catalytic domain across planar phospholipid bilayers. Int. J. Med. Microbiol. 2000, 290 (4–5), 435–440.
      122. Gordon M., Finkelstein A. The number of subunits comprising the channel formed by the T domain of diphtheria toxin. J. Gen. Physiol. 2001, 118 (5), 471–480.
      123. Finkelstein A. Proton-coupled protein transport through the anthrax toxin channel. Philos Trans. R Soc. Lond. B Biol. Sci. 2009, 364 (1514), 209–215.
      124. Deleers M., Beugnier N., Falmagne P., Cabiaux V., Ruysschaert J. M. Localization in diphtheria toxin fragment B of a region that induces pore formation in planar lipid bilayers at low pH. FEBS Lett. 1983, 160 (1–2), 82–86.
      125. Shiver J. W., Donovan J. J. Interactions of diphtheria toxin with lipid vesicles: determinants of ion channel formation. Biochim. Biophys. Acta. 1987, 903 (1), 48–55.
      126. Murphy J. R. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins (Basel). 2011, 3 (3), 294–308.
      127. Saito M., Iwawaki T., Taya C., Yonekawa H., Noda M., Inui Y., Mekada E., Kimata Y.,Tsuru A., Kohno K. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 2001, 19 (8), 746–750.
      128. Furukawa N., Saito M., Hakoshima T., Kohno K. A diphtheria toxin receptor deficient in epidermal growth factorlike biological activity. J. Biochem. 2006, 140 (6), 831–841.
      129. Matsuoka K., Saito M., Shibata K., Sekine M., Shitara H., Taya C., Zhang X., Takahashi T. A., Kohno K., Kikkawa Y., Yonekawa H. Generation of mouse models for type 1 diabetes by selective depletion of pancreatic beta cells using toxin receptormediated cell knockout. Biochem. Biophys. Res. Commun. 2013, 436 (3), 400–405.
      130. Jung S., Unutmaz D., Wong P., Sano G.-I., De los Santos K., Sparwasser T., Wu S., Vuthoori S., Ko K., Zavala F., Pamer E. G., Littman D. R., Lang R. A. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002, 17 (2), 211–220.
      131. Bennett C. L., van Rijn E., Jung S., Inaba K., Steinman R. M., Kapsenberg M. L., Clausen B. E. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell Biol. 2005, 169 (4), 569–576.
      132. Ruedl C., Jung S. DTR-mediated conditional cell ablation-Progress and challenges. Eur. J. Immunol. 2018, 48 (7), 1114–1119.
      133. Aguila H. L., Hershberger R. J., Weissman I. L. Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells. Proc. Natl. Acad. Sci. U S A. 1995, 92 (22), 10192–10196.
      134. Brockschnieder D., Lappe-Siefke C., Goebbels S., Boesl M. R., Nave K.-A., Riethmacher D. Cell depletion due to diphtheria toxin fragment A after Cre-mediated recombination. Mol. Cell. Biol. 2004, 24 (17), 7636–7642. doi: 10.1128/MCB.24.17.7636-7642.2004.
      135. Nakamura S., Terashima M., Kikuchi N., Kimura M., Maehara T., Saito A., Sato M. A new mouse model for renal lesions produced by intravenous injection of diphtheria toxin A-chain expression plasmid. BMC Nephrol. 2004, 54. doi: 10.1186/1471-2369-5-4.
      136. Lang R. A., Bishop J. M. Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell. 1993, 74 (3), 453–462.
      137. Brockschnieder D., Pechmann Y., Sonnenberg-Riethmacher E., Riethmacher D. An improved mouse line for Cre-induced cell ablation due to diphtheria toxin A, expressed from the Rosa26 locus. Genesis. 2006, 44 (7), 322–327.
      138. Frank A. C., Johnson M. A. Expressing the Diphtheria Toxin A Subunit from the HAP2(GCS1) Promoter Blocks Sperm Maturation and Produces Single Sperm-Like Cells Capable of Fertilization. Plant Physiol. 2009, 151 (3), 1390–1400.
      139. Talbird S. E., Graham J., Mauskopf J., Masseria C., Krishnarajah G. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases. J. Manag. Care Spec. Pharm. 2015, 21 (1), 88–99, 99a-c.
      140. Rappuoli R., Bagnoli F. Vaccine Design: Innovative Approaches and Novel Strategies. Horizon Scientific Press, 2011.
      141. Robbins J. B., Schneerson R., Keith J. M., Miller M. A., Kubler-Kielb J., Trollfors B. Pertussis vaccine: a critique. Pediatr. Infect. Dis. J. 2009, 28 (3), 237–241.
      142. Mooi F. R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect. Genet. Evol. 2010, 10 (1), 36–49.
      143. Pichichero M. E. Protein carriers of conjugate vaccines. Hum. Vaccin. Immunother. 2013, 9 (12), 2505–2523.
      144. Shinefield H. R. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use. Vaccine. 2010, 28 (27), 4335–4339.
      145. Bröker M., Costantino P., DeTora L., McIntosh E. D., Rappuoli R. Biochemical and biological characteristics of crossreacting material 197 CRM197, a nontoxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals. 2011, 39 (4), 195–204.
      146. Buzzi S., Maistrello I. Inhibition of growth of Erlich tumors in Swiss mice by diphtheria toxin. Cancer Res. 1973, 33 (10), 2349–2353.
      147. Tang X.-H., Deng S., Li M., Lu M.-S. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxelresistant human ovarian cancer. Tumour Biol. 2016, 37 (4), 5521–5528.
      148. Yagi H., Yotsumoto F., Sonoda K., Kuroki M., Mekada E., Miyamoto S. Synergistic antitumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int. J. Cancer. 2009, 124 (6), 1429–1439.
      149. Nam S.O., Yotsumoto F., Miyata K., Fukagawa S., Odawara T., Manabe S., Ishikawa T., Kuroki M., Yasunaga S., Miyamoto S. Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy. Anticancer Res. 2016, 36 (7), 3651–3657.
      150. Buzzi S., Rubboli D., Buzzi G., Buzzi A. M., Morisi C., Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol. Immunother. 2004, 53 (11), 1041–1048.
      151. Tsujioka H., Fukami T., Yotsumoto F., Ueda T., Hikita S., Takahashi Y., Kondo H., Kuroki M., Miyamoto S. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res. 2011, 31 (7), 2461–2465.
      152. Lian C., Ruan L., Shang D., Wu Y., Lu Y., L P., Yang Y., Wei Y., Dong X., Ren D., Chen K., Liu H., Tu Z. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy. Cancer Biother. Radiopharm. 2016, 31 (3), 85–90.
      153. Yotsumoto F., Oki E., Tokunaga E., Maehara Y., Kuroki M., Miyamoto S. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int. J. Cancer. 2010, 127 (11), 2707–2717.
      154. Dateoka S., Ohnishi Y., Kakudo K. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer. Med. Mol. Morphol. 2012, 45 (2), 91–97.
      155. Sanui A., Yotsumoto F., Tsujioka H., Fukami T., Horiuchi S., Shirota K., Yoshizato T., Kawarabayashi T., Kuroki M., Miyamoto S. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res. 2010, 30 (8), 3143–3149.
      156. Kunami N., Yotsumoto F., Ishitsuka K., Fukami T., Odawara T., Manabe S., Ishikawa T., Tamura K., Kuroki M., Miyamoto S. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia. Anticancer Res. 2011, 31 (7), 2483–2488.
      157. Wang F., Liu R., Lee S.W., Sloss C.M., Couget J., Cusack J.C. Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene. 2007, 26 (14), 2006–2016.
      158. Zhou Z. N., Sharma V. P., Beaty B. T., Roh-Johnson M., Peterson E. A., Van Rooijen N., Kenny P. A., Wiley H. S., Condeelis J. S., Segall J. E. Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene. 2014, 33 (29), 3784–3793.
      159. Frankel A. E., Woo J. H., Ahn C., Foss F. M., Duvic M., Neville P. H., Neville D. M. Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015, 100 (6), 794–800.
      160. Wolska-Washer A., Robak P., Smolewski P., Robak T. Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opin. Emerg. Drugs. 2017, 22 (3), 259–273.
      161. Schmohl J. U., Todhunter D., Taras E., Bachanova V., Vallera D. A. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins (Basel). 2018, 10 (1).
      162. Zheng Q., Wang Z., Zhang H., Huang Q., Madsen J. C., Sachs D. H., Huang C. A., Wang Z. Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors. Mol. Oncol. 2017, 11 (5), 584–594.
      163. Kreitman R. J., Tallman M. S., Robak T., Coutre S., Wilson W. H., Stetler-Stevenson M., FitzGerald D. J., Santiago L., Gao G., La nasa M. C., Pastan I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018, 131 (21), 2331–2334.
      164. Wayne A. S., Shah N. N., Bhojwani D., Silverman L. B., Whitlock J. A., Stetler-Steven son M., Sun W., Liang M., Yang J., Kreitman R. J., Lanasa M. C., Pastan I. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017, 130 (14), 1620–1627.
      165. Woo J. H., Lee Y.-J., Neville D. M., Frankel A. E. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials. Meth. Mol. Biol. 2010, 651157–651175.
      166. Thompson J., Hu H., Scharff J., Neville D. M. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J. Biol. Chem. 1995, 270 (47), 28037–28041.
      167. Wang Z., Wei M., Zhang H., Chen H., Germana S., Huang C. A., Madsen J. C., Sachs D. H., Wang Z. Diphtheria-toxin based antihuman CCR4 immunotoxin for targeting human CCR4(+) cells in vivo. Mol Oncol. 2015, 9 (7), 1458–1470.
      168. Testa U., Riccioni R., Biffoni M., Diverio D., Lo-Coco F., Fo R., Peschle C., Frankel A. E. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood. 2005, 106 (7), 2527–2529.
      169. Wen Z. L., Tao X., Lakkis F., Kiyokawa T., Murphy J. R. Diphtheria toxin-related alphamelanocyte-stimulating hormone fusion toxin. Internal in-frame deletion from Thr387 to His485 results in the formation of a highly potent fusion toxin which is resistant to proteolytic degradation. J. Biol. Chem. 1991, 266 (19), 12289–12293.
      170. Zhang Y., Schulte W., Pink D., Phipps K., Zijlstra A., Lewis J. D., Waisman D. M. Sensitivity of cancer cells to truncated diphtheria toxin. PLoS ONE. 2010, 5 (5), e10498.
      171. Ramakrishnan S., Olson T. A., Bautch V. L., Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 1996, 56 (6), 1324–1330.
      172. Wild R., Yokoyama Y., Dings R. P. M., Ramakrishnan S. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res. Treat. 2004, 85 (2), 161–171.
      173. Murphy J. R., Bishai W., Borowski M., Miyanohara A., Boyd J., Nagle S. Genetic construction, expression, and melanomaselective cytotoxicity of a diphtheria toxinrelated alpha-melanocyte-stimulating hormone fusion protein. Proc. Natl. Acad. Sci. U.S.A. 1986, 83 (21), 8258–8262.
      174. Williams D. P., Wen Z., Watson R. S., Boyd J., Strom T. B., Murphy J. R. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J. Biol. Chem. 1990, 265 (33), 20673–20677.
      175. Chan C. H., Blazar B. R., Greenfield L., Kreitman R. J., Vallera D. A. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells. Blood. 1996, 88 (4), 1445–1456.
      176. Black J. H., McCubrey J. A., Willing ham M. C., Ramage J., Hogge D. E., Frankel A. E. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia. 2003, 17 (1), 155–159.
      177. Cohen K. A., Liu T. F., Cline J. M., Wagner J. D., Hall P. D., Frankel A. E. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leuk. Lymphoma. 2004, 45 (8), 1647–1656.
      178. Li Y. M., Vallera D. A., Hall W. A. Diphtheria toxin-based targeted toxin therapy for brain tumors. J. Neurooncol. 2013, 114 (2), 155–164.
      179. Chadwick D. E., Williams D. P., Niho Y., Murphy J. R., Minden M. D. Cytotoxicity of a recombinant diphtheria toxin-granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk. Lymphoma. 1993, 11 (3–4), 249–262.
      180. Hotchkiss C. E., Hall P. D., Cline J. M., Willingham M. C., Kreitman R. J., Gardin J., Latimer A., Ramage J., Feely T., DeLatte S., Tagge E. P., Frankel A. E. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocytemacrophage colony-stimulating factor, in cynomolgus monkeys. Toxicol. Appl. Pharmacol. 1999, 158 (2), 152–160.
      181. Hall P.D., Willingham M.C., Kreitman R.J., Frankel A.E. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocytemacrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999, 13 (4), 629–633.
      182. Feuring-Buske M., Frankel A., Gerhard B., Hogge D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colonystimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp. Hematol. 2000, 28 (12), 1390–1400.
      183. Ramage J. G., Vallera D. A., Black J. H., Ap lan P. D., Kees U. R., Frankel A. E. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk. Res. 2003, 27 (1), 79–84.
      184. Hagihara N., Walbridge S., Olson A. W., Oldfield E. H., Youle R. J. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000, 60 (2), 230–234.
      185. Kreitman R. J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8 (3), E532-551.
      186. Wayne A. S., FitzGerald D. J., Kreit man R. J., Pastan I. Immunotoxins for leukemia. Blood. 2014, 123 (16), 2470–2477.
      187. Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007, 7 (1), 11–17.
      188. Duvic M., Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008, 4 (4), 457–469.
      189. Urieto J. O., Liu T., Black J. H., Cohen K. A., Hall P. D., Willingham M. C., Pennell L. K., Hogge D. E., Kreitman R. J., Frankel A. E. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr. Purif. 2004, 33 (1), 123–133.
      190. Hogge D. E., Yalcintepe L., Wong S.-H., Gerhard B., Frankel A. E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin. Cancer Res. 2006, 12 (4), 1284–1291.
      191. Orr N., Galen J. E., Levine M. M. Expression and Immunogenicity of a Mutant Diphtheria Toxin Molecule, CRM197, and Its Fragments in Salmonella typhi Vaccine Strain CVD 908-htrA. Infect Immun. 1999, 67 (8), 4290–4294.
      192. Kaberniuk A. A., Oliinyk O. S., Kolybo D. V., Komisarenko S. V. Toxin-neutralizing properties of antibodies to diphtheria toxin recombinant subunits A and B and a new method of their estimation. Ukr. Biokhim. Zh. (1999). 2009, 81 (3), 92–101. (In Ukrainian).
      193. Pavlov P. V., Leonova A. G. Effect of the products of protein splitting in the culture medium on toxin formation. II. Antigen and immunogenic properties of diphtheria toxins (toxoids) obtained on the medium, digested by 2 enzymes, during culture of the Weisensee strain. Zh. Mikrobiol. Epidemiol. Immunobiol. 1961, 32, 95–99. (In Russian).
      194. Romaniuk S. I., Kolibo D. B., Komisarenko S. V. Perspectives of application of recombinant diphtheria toxin derivatives. Bioorg. Khim. 2012, 38 (6), 639–652.
      195. Liu W., Onda M., Lee B., Kreitman R. J., Hassan R., Xiang L., Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (29), 11782–11787.
      196. Mazor R., Onda M., Pastan I. Immunogenicity of therapeutic recombinant immunotoxins. Immunol. Rev. 2016, 270 (1), 152–164.
      197. Onda M., Beers R., Xiang L., Nagata S., Wang Q.-C., Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (32), 11311–11316.
      198. Flavell D. J. Countering immunotoxin immunogenicity. Br. J. Cancer. 2016, 114 (11), 1177–1179.